Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Biological: Ramucirumab (IMC-1121B)
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 141
- Registration Number
- NCT01427933
- Locations
- 🇺🇸
ImClone Investigational Site, Vancouver, Washington, United States
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT01418677
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 127
- Registration Number
- NCT01401959
- Locations
- 🇺🇸
The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇺🇸Mercy Hospital, Portland, Maine, United States
🇺🇸Texas Health Physician Group, Arlington, Texas, United States
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
- Conditions
- HER-2 Positive Breast Cancer
- Interventions
- First Posted Date
- 2011-07-07
- Last Posted Date
- 2015-08-28
- Lead Sponsor
- Vector Oncology
- Target Recruit Count
- 12
- Registration Number
- NCT01388647
- Locations
- 🇺🇸
Northwest Georgia Oncology Centers, Marietta, Georgia, United States
🇺🇸Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸Northeast Georgia Cancer Care, Athens, Georgia, United States
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
- Conditions
- Male Breast CancerStage II Breast CancerEstrogen Receptor-negative Breast CancerProgesterone Receptor-negative Breast CancerStage IA Breast CancerStage IIIC Breast CancerTriple-negative Breast CancerHER2-negative Breast CancerStage IB Breast CancerStage IIIA Breast Cancer
- Interventions
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 30
- Registration Number
- NCT01372579
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 452
- Registration Number
- NCT01327885
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT01328249
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center ,Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Confirmation Study of Eribulin in Combination With Capecitabine
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 76
- Registration Number
- NCT01323530
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
- First Posted Date
- 2011-01-04
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01269346
- Locations
- 🇺🇸
Heartland Regional Medical Center, Saint Joseph, Missouri, United States
🇺🇸Texas Oncology - Medical City Dallas, Dallas, Texas, United States
🇺🇸Peachtree Hematology Oncology Associates, PC, Atlanta, Georgia, United States
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
- Conditions
- Metastatic Breast Cancer ( HER2 Negative)Locally Recurrent
- Interventions
- First Posted Date
- 2010-12-29
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01268150
- Locations
- 🇺🇸
Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States
🇺🇸Augusta Oncology Associates, Augusta, Georgia, United States
🇺🇸Central Georgia Cancer Care, Macon, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.